Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 2, 2016

View Archived Issues

New biomarkers in rheumatoid disease presented at ACR meeting

Arsanis' ASN-100 receives FDA fast track designation

ABC-1183, a novel GSK3/CDK9 inhibitor

EC grants orphan designation to Agilis Biotherapeutics' AGIL-AADC

AmorePacific initiates phase III trial of PAC-14028 in atopic dermatitis

Vertex initiates phase II study of VX-152 combination therapy for cystic fibrosis

A first-in-class small-molecule inhibitor of PD-L1 and TIM-3

Daiichi Sankyo's DS-8201 given FDA fast track designation

First phase Ia/b data for anti-RSPO3 antibody OMP-131R10 in advanced solid tumors

City of Hope and TGen form alliance to advance precision medicine

Axial Biotherapeutics launches with series A financing

Portage Biotech forms new ophthalmic-focused company

Kalyra Pharmaceuticals patents EGFR inhibitors

Wistar Institute discloses EBNA-1 inhibitors

GlaxoSmithKline describes RIP-1 kinase 1 inhibitors

Medshine Discovery develops PDE2A inhibitors and TNF-alpha production inhibitors

Kainos Medicine presents Brd4 inhibitors

Aequus BioPharma synthesizes melanocortin fusion peptide for treating gout

IONIS-ANGPTL3-LRx shows potential to reduce plasma ANGPTL3 and lipids

Ferring Pharmaceuticals and Ache Laboratorios Farmaceuticos form nanotechnology collaboration

Biophytis' Sarconeos safe in SARA-PK clinical study

Aradigm reports topline results from ORBIT-3 and -4 studies of Pulmaquin

Inovio Pharmaceuticals awarded grant for MAb against Zika virus

GALACTIC-HF phase III trial of omecamtiv mecarbil begins

HDAC6 inhibitor ACY-241 given U.S. orphan status for multiple myeloma

Dosing begins in phase I/II study of Agenus' INCAGN-1949

Shire's Cinryze granted U.S. orphan status for acute antibody-mediated renal transplant rejection